Elizabeth Gaughan headshot
EG

Elizabeth M. Gaughan

Associate Professor
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
Education
Residency, Beth Israel Deaconess Medical Center
Fellowship, Beth Israel Deaconess Medical Center
MD, Georgetown University School of Medicine
Biography

Dr. Gaughan received her MD degree from Georgetown University School of Medicine. She completed her medical residency and hematology/medical oncology fellowship at the Beth Israel Deaconess Medical Center, part of Harvard Medical School. She joined the University of Virginia in 2012 with a clinical focus on caring for patients with melanoma, head and neck cancer and genitourinary malignancies. She is an active participant in the clinical trial process at the Emily Couric Clinical Cancer Center and is interested in the education and training of residents and fellows. Dr. Gaughan is a member of several national and local medical societies.

Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study
Source: ECOG-ACRIN Cancer Research Group
May 01, 2021 – April 30, 2026
Phase 1B/2 Study of PAC-1 and Entrectinib for Patients with Metastatic Uveal Melanoma
Source: Hoosier Cancer Research Network, Inc.
May 12, 2021 – May 11, 2024
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Source: ECOG-ACRIN Cancer Research Group
November 17, 2020 – November 16, 2023
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY
Source: Regeneron Pharmaceuticals, Inc.
March 17, 2020 – March 16, 2023
A Phase III Randomized Trial Comparing Adjuvant MK- 3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Source: ECOG-ACRIN Cancer Research Group
March 13, 2019 – March 12, 2022
MD-INMD-HO A Phase 3 Clinical Trial of Pembrolizumab (MD-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Source: Merck Sharp & Dohme Corp.
July 28, 2015 – January 28, 2022
Virginia Kincaid Cancer Research Fund
Source: Virginia Kincaid Charitable Trust
October 01, 2005 – December 31, 2021
MD-INMD-HO Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in patients with Unresectable Stage III or Stage IV Melanoma
Source: ECOG-ACRIN Cancer Research Group
January 15, 2016 – November 01, 2021
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Source: ECOG-ACRIN Cancer Research Group
September 01, 2018 – August 31, 2021
MD-CANC ECOG-ACRIN Master
Source: ECOG-ACRIN Cancer Research Group
May 01, 2016 – April 30, 2021
MD-INMD-HO Clinical Validation of Prediction of Immunotherapy Therapy response using PD1/PDL1 Interaction Measured by Quantitative Multiplex FIHC AQUA Test
Source: Genoptix, Inc.
April 06, 2016 – February 13, 2019
MD-INMD Expanded Access of MK-3475 in Metastatic Melanoma Patients with Limited to No Treatment Options
Source: Merck Sharp & Dohme Corp.
June 02, 2014 – June 02, 2018
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance (ETCTN 9922)
Source: Johns Hopkins University
February 23, 2017 – May 01, 2018
Protocol CDX1127-01
Source: Celldex Therapeutics, Inc.
December 01, 2011 – June 30, 2016